Variability in the TLR3–type I interferon pathway before vaccination is associated with the strength of T‑cell responses following mRNA COVID‑19 vaccination. The InnoHK Centre for Immunology & Infection (InnoHK C2i), established through a strategic partnership between The University of Hong Kong (HKU) and the Institut Pasteur, together with collaborators from Milieu Interieur (Institut Pasteur), the Department of Paediatrics and Adolescent Medicine (HKU), the School of Publi

The Healthy Human Global Project - Hong Kong : a community-based cross-sectional study of a healthy Asian population The InnoHK Centre for Immunology & Infection (InnoHK C2i), established through a strategic partnership between The University of Hong Kong (HKU) and the Institut Pasteur, together with the Institut Pasteur Milieu Interieur (MI) , FAMILY Cohort (HKU, School of Public Health) and the Centre for Sports and Exercise (HKU CSE) have established the Healthy Hum

The vaccine not only prevents severe disease, but also effectively blocks viral transmission in animal models, offering a promising strategy for pandemic preparedness against future coronavirus threats. A research team at the LKS Faculty of Medicine, the University of Hong Kong (HKUMed), has developed a novel live-attenuated vaccine candidate, cb1, capable of generating broad immunity against a wide range of beta-coronaviruses with a single intranasal dose. The vaccine not on

Professor Michael Chan , Lead Scientist at C2i and CEO of C2iTech , was featured on RTHK's "Under the Sun" (太陽底下新鮮事) radio show, diving deep into the fascinating realm of organoid development! From lab breakthroughs to real-world impacts on medicine: https://www.rthk.hk/radio/radio1/programme/underthesun

The InnoHK Centre for Immunology & Infection Limited (C2i) and its spin-off C2iTech Limited have signed a Memorandum of Understanding (MOU) with Guangzhou Jingke Biotech Co., Ltd. and Shenzhen Jingke Biotech Co., Ltd. to advance patient-derived organoid (PDO) technologies for personalized oncology. The signing parties were represented by Professor Leo Poon , Managing Director, C2i; Professor Michael Chan , CEO, C2iTech; Mr. Sheng Li, Chairman, Jingke Biotech Group, and Profes

On the occasion of a joint seminar celebrating their partnership established in 2023, the Centre for Immunology & Infection Limited (C2i)...